Floatz logo

azd7503

Fatty Liver, Nonalcoholic

AstraZenecaPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Fatty Liver, Nonalcoholic cohort.

Asset / SponsorPhaseRating
S-Adenosyl-L-Methionine
Cedars-Sinai Medical Center
Phase 3BB
htd1801
HighTide Biopharma Pty Ltd
Phase 2B
VUPANORSEN
Akcea Therapeutics
Phase 2B
met409 active
Metacrine, Inc.
Phase 2CCC
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Sadat City University
Phase 1/2CCC
PITAVASTATIN
Massachusetts General Hospital
N/AD
Dietary Supplement "Gepaktiv"
Phenomen Pharma
N/AD

Same molecule, other indications

azd7503 is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
CC
Indicative ·
46 / 100
View asset →
NASHDormant
CC
Indicative ·
46 / 100
View asset →
SteatohepatitisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →